US OptionsDetailed Quotes
BCTX241220C1000
- 0.05
- +0.01+25.00%
15min DelayClose Dec 13 16:00 ET
0.05High0.05Low
0.05Open0.04Pre Close61 Volume536 Open Interest1.00Strike Price305.00Turnover392.41%IV59.09%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier6DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.2955Delta1.0058Gamma13.20Leverage Ratio-0.0094Theta0.0000Rho3.90Eff Leverage0.0003Vega
BriaCell Therapeutics Stock Discussion
Sign in to post a comment
$Gorilla Technology (GRRR.US)$ PR: CEO will have interview with Red Chip Small Stock, Big Money show on Sat Dec 14. Reports on CEO on X that they have been selected from the shortlist for the $438M deal in SE Asia. Low float. $23.2M cash good for 12 months
$Checkpoint Therapeutics (CKPT.US)$ $Fortress Biotech (FBIO.US)$ FDA approval of drug for metastatic cutaneous squamous cell carcinoma. This drug is the first and only progr...
$Checkpoint Therapeutics (CKPT.US)$ $Fortress Biotech (FBIO.US)$ FDA approval of drug for metastatic cutaneous squamous cell carcinoma. This drug is the first and only progr...
10
24
$BriaCell Therapeutics (BCTX.US)$ Briacell Therapeutics Highlights The Infiltration Of Cancer Fighting Immune Cells Into Tumors, Using CD8 ImmunoPET Imaging Technology, In Its Poster Presentation At 2024 San Antonio Breast Cancer Symposium
Benzinga· 1 min ago
Benzinga· 1 min ago
1
2
$BriaCell Therapeutics (BCTX.US)$
BriaCell 2024 SABCS® Poster Highlights Ability of Bria-IMT™ Regimen to Increase Cancer-Fighting Immune Cells in Metastatic Breast Cancer
Friday, 13th December at 7:50 am
BriaCell reports influx of cancer fighting CD8+ "killer" T cell into metastatic breast cancer tumors and lymph organs turning "Cold" tumors and lymph nodes "Hot" on ImmunoPET imaging in cancer patients treated with Bria-IMT™ plus an immune checkpoint inhibitor (CPI)
Imaging confirms clinical...
BriaCell 2024 SABCS® Poster Highlights Ability of Bria-IMT™ Regimen to Increase Cancer-Fighting Immune Cells in Metastatic Breast Cancer
Friday, 13th December at 7:50 am
BriaCell reports influx of cancer fighting CD8+ "killer" T cell into metastatic breast cancer tumors and lymph organs turning "Cold" tumors and lymph nodes "Hot" on ImmunoPET imaging in cancer patients treated with Bria-IMT™ plus an immune checkpoint inhibitor (CPI)
Imaging confirms clinical...
3
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$BriaCell Therapeutics (BCTX.US)$ Bearish news - Offering but no bad news about the company. Low risk, big reward potential imo. My SL below 0.50.
1
5
$BriaCell Therapeutics (BCTX.US)$ Reuters· 2 mins ago
Briacell Therapeutics Announces Proposed Public Offering
Briacell Therapeutics Announces Proposed Public Offering
3
19
$BriaCell Therapeutics (BCTX.US)$
BriaCell Presents Unprecedented Overall Survival Data in Metastatic Breast Cancer in Spotlight Poster at 2024 SABCS®
Wednesday, 11th December at 7:50 am
Median overall survival (OS) to date of 13.4 months for Phase 2 patients treated with the Phase 3 formulation (15.6 months for those treated since 2022), double that of comparable patients in the literature
Final Phase 2 OS calculation is pending as many patients remain alive well over 1 year after starting...
BriaCell Presents Unprecedented Overall Survival Data in Metastatic Breast Cancer in Spotlight Poster at 2024 SABCS®
Wednesday, 11th December at 7:50 am
Median overall survival (OS) to date of 13.4 months for Phase 2 patients treated with the Phase 3 formulation (15.6 months for those treated since 2022), double that of comparable patients in the literature
Final Phase 2 OS calculation is pending as many patients remain alive well over 1 year after starting...
$BriaCell Therapeutics (BCTX.US)$ Pending good news leak out ?
1
$BriaCell Therapeutics (BCTX.US)$ The Data Safety Monitoring Board Has Completed Its First Review Of Safety Events In Patients Enrolled In BriaCell Therapeutics' Phase 3 Study Of Bria-IMT Plus An Immune Checkpoint Inhibitor, Recommending Continuation Of The Study In Metastatic Breast Cancer Patients
The Data Safety Monitoring Board (DSMB) stated no safety concerns, and recommended continuation of BriaCell's pivotal Phase 3 study of Bria-IMT plus ...
The Data Safety Monitoring Board (DSMB) stated no safety concerns, and recommended continuation of BriaCell's pivotal Phase 3 study of Bria-IMT plus ...
2
1
No comment yet
HannChau : any thought on BCTX?
Jaguar8 OP HannChau : I’m hoping it will recover too since it closed its offering today
HannChau Jaguar8 OP : haha, i went in again. I think it will go back to 1 soon![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
S2ET0 HannChau : 我還在1.04![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
Jaguar8 OP HannChau : I’ll just re-enter PM hoping no offering is announce over the weekend
View more comments...